Eventide Asset Management LLC Has $17.44 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Eventide Asset Management LLC cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 29.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,781 shares of the company's stock after selling 40,704 shares during the period. Eventide Asset Management LLC owned about 0.33% of Krystal Biotech worth $17,435,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Key Financial Inc acquired a new stake in Krystal Biotech in the 2nd quarter valued at $28,000. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after acquiring an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech during the second quarter worth about $28,000. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in Krystal Biotech in the third quarter valued at approximately $53,000. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

KRYS traded up $0.51 on Friday, reaching $197.42. The company had a trading volume of 116,614 shares, compared to its average volume of 324,187. The stock has a market cap of $5.68 billion, a P/E ratio of 111.54 and a beta of 0.82. Krystal Biotech, Inc. has a fifty-two week low of $100.78 and a fifty-two week high of $219.34. The company's fifty day moving average is $180.49 and its 200 day moving average is $183.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the business earned ($0.67) earnings per share. The firm's revenue for the quarter was up 879.9% on a year-over-year basis. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of analyst reports. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research note on Monday, August 12th. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. Finally, Chardan Capital lifted their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $202.29.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).